1. Signaling Pathways
  2. GPCR/G Protein
  3. GLP Receptor

GLP Receptor

GLP Receptor

The GLP receptors contain two family members, GLP-1 receptor (GLP1R, or GLP-1R) and GLP-2 receptor (GLP2R or GLP-1R), activated by the glucagon-like peptides (GLPs). GLPs are s secreted by intestinal cells; causes insulin release; inhibits glucagon secretion, appetite, and energy intake; and delays gastric emptying because GLP receptors are located on the gut, pancreas, brainstem, hypothalamus, and vagal-afferent nerves. GLP-1 has only one known receptor, GLP1R, and regulates gut motility, appetite, islet function, and glucose homeostasis, whereas GLP-2, the agonist of GLP2R, enhances intestinal nutrient absorption. GLP-1R agonists are used to treat diabetes and obesity, and a GLP-2R agonist is approved to treat short bowel syndrome. An investigation of the actions of GLP receptor activation on gallbladder motility has demonstrated that GLP-2 receptor activation increases gallbladder volume in vivo and decreases spontaneous activity in GBSM bundles ex vivo. Like the inhibitory transmitters, which elicit their actions via an adenylate cyclase-protein kinase A-KATP channel pathway, the GLP-2 receptor signals through this same pathway.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P0014S1
    Liraglutide-13C5,15N TFA
    98.19%
    Liraglutide-13C5,15N (tetraTFA) is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
    Liraglutide-<sup>13</sup>C<sub>5</sub>,<sup>15</sup>N TFA
  • HY-164535
    Maridebart cafraglutide
    Agonist
    Maridebart cafraglutide (AMG 133) is an antibody-peptide conjugate acting as a GLP-1 receptor agonist and an antagonist of the GIP receptor. Maridebart cafraglutide reduces body weight and improve metabolic markers in male obese mice and cynomolgus monkeys. Maridebart cafraglutide is promising for research of obesity.
    Maridebart cafraglutide
  • HY-160734
    Aleniglipron
    Agonist 99.88%
    Aleniglipron (compound 121a) (GSBR-1290) is a GLP-1 agonist with an EC50 value of less than 0.1 nM in the HDB cell line in a cAMP stimulation assay.
    Aleniglipron
  • HY-143312A
    V-0219 hydrochloride
    Modulator 99.65%
    V-0219 hydrochloride (Compound 9) is an orally active, positive allosteric modulator (PAM) of the glucagon-like peptide-1 receptor (GLP-1R). V-0219 hydrochloride can be used for obesity-associated diabetes research.
    V-0219 hydrochloride
  • HY-P1714A
    Apraglutide TFA
    98.69%
    Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum.
    Apraglutide TFA
  • HY-P10031A
    SAR441255 TFA
    Agonist 99.93%
    SAR441255 TFA is a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist. SAR441255 TFA displays high potency with balanced activation of all three target receptors.?SAR441255 TFA shows positive acute glucoregulatory effectss in diabetic obese monkeys.
    SAR441255 TFA
  • HY-P990047
    Maridebart
    Inhibitor 98.23%
    Maridebart is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody.
    Maridebart
  • HY-P10018
    Bamadutide
    Agonist 99.96%
    Bamadutide (SAR425899) is a potent dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist. Bamadutide improves post-meal blood glucose control by significantly enhancing β-cell function and slowing down the rate of glucose absorption in the body. Bamadutide can be used for the research of metabolic diseases such as type 2 diabetes.
    Bamadutide
  • HY-153815
    GLP-1 receptor agonist 11
    Agonist 98.01%
    GLP-1 receptor agonist 11 (compound 3) is an agonist of GLP Receptor. GLP-1 receptor agonist 11 can be used in the study of diseases such as diabetes and non-alc. fatty liver disease.
    GLP-1 receptor agonist 11
  • HY-143312E
    (S)-V-0219 hydrochloride
    Modulator 99.71%
    (S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice.
    (S)-V-0219 hydrochloride
  • HY-P10302A
    GLP-1R/GIPR agonist-1 (soduim)
    Agonist
    GLP-1R/GIPR agonist-1 soduim is the sodium salt form of GLP-1R/GIPR agonist-1 (HY-P10302). GLP-1R/GIPR agonist-1 soduim is a dual agonist for glucagon-like peptide-1 receptor (GLP-1R, EC50 is 0.57 nM) and glucose-dependent insulin releasing peptide receptor (GIPR, EC50 is 0.75 nM). GLP-1R/GIPR agonist-1 soduim lowers blood sugar by mimicking the action of endogenous hormones GLP-1 and GIP, enhancing insulin secretion while inhibiting glucagon secretion. GLP-1R/GIPR agonist-1 soduim can be used in the study of metabolic diseases such as diabetes, obesity, and non-alcoholic steatohepatitis (NASH).
    GLP-1R/GIPR agonist-1 (soduim)
  • HY-P10032A
    NN1177 TFA
    Agonist 98.66%
    NN1177 (NNC9204-1177) TFA is a long-acting GLP-1/glucagon receptor co-agonist. NN1177 TFA can induce a dose-dependent body weight loss in diet-induced obese (DIO) mice.
    NN1177 TFA
  • HY-156968
    GLP-1 receptor agonist 14
    Agonist 98.78%
    GLP-1 receptor agonist 14 (compound 73) is a potent agonist of glucagon-like peptide-1 (GLP-1). GLP-1 receptor agonist 14 plays an important role in diabetes or other metabolic disorders.
    GLP-1 receptor agonist 14
  • HY-147625
    GLP-1R agonist 12
    Agonist
    GLP-1R agonist 12 (Compound 123) is an agonist of glucagon-like peptide-1 receptors (GLP-1R). GLP-1R agonist 12 can be used for diabetes research.
    GLP-1R agonist 12
  • HY-143312D
    (R)-V-0219 hydrochloride
    Modulator 99.37%
    (R)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (R)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R.
    (R)-V-0219 hydrochloride
  • HY-153798
    GLP-1 receptor agonist 10
    Agonist 99.51%
    GLP-1 receptor agonist 10 (compound 42) is an agonist of GLP Receptor. GLP-1 receptor agonist 10 inhibits food intake and reduces glucose excursion in mice. GLP-1 receptor agonist 10 can be used in the study of type 2 diabetes (T2DM) and obesity.
    GLP-1 receptor agonist 10
  • HY-147623
    GLP-1R agonist 10
    Agonist 98.99%
    GLP-1R agonist 10 (Compound 109a) is a GLP-1 agonist with an EC50 of 0.051 nM.
    GLP-1R agonist 10
  • HY-153816
    GLP-1 receptor agonist 12
    Agonist
    GLP-1 receptor agonist 12 (compound 20A) is an agonist of GLP Receptor. GLP-1 receptor agonist 12 can be used in the study of diseases such as diabetes.
    GLP-1 receptor agonist 12
  • HY-P5815A
    GLP-1 (1-36) amide (human, rat) TFA
    98.81%
    GLP-1 (1-36) amide (human, rat) (Glucagon-like Peptide 1 (1-36) amide (human, rat) ) TFA is a molecular variant of glucagon-like peptide 1 (GLP-1)-(7-36) amide. GLP-1 (1-36) amide (human, rat) TFA can stimulate [14C]aminopyrine accumulation on enzymatically dispersed enriched rat parietal cells.
    GLP-1 (1-36) amide (human, rat) TFA
  • HY-153193
    LSN3160440
    Modulator
    LSN3160440 is an allosteric modulator of GLP-1R, which acts as a protein–protein interaction (PPI) stabilizer or molecular glue to assist in the adhesion of inactive GLP-1 (9-36) NH2 on GLP-1R.
    LSN3160440
Cat. No. Product Name / Synonyms Application Reactivity